Survival Advantage of ADT+RT in Prostate CA Extends to Older Men

This article originally appeared here.
Share this content:
Survival Advantage of ADT+RT in Prostate CA Extends to Older Men
Survival Advantage of ADT+RT in Prostate CA Extends to Older Men

(HealthDay News) -- Androgen-deprivation therapy with radiotherapy (ADT plus RT) is associated with a survival advantage over ADT alone for older men with locally advanced or screen-detected high-risk prostate cancer, according to a study published online Jan. 5 in the Journal of Clinical Oncology.

Justin E. Bekelman, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues conducted nonrandomized effectiveness studies of ADT plus RT versus ADT in three cohorts of patients diagnosed between 1995 and 2007. The randomized clinical trial (RCT) cohort included men aged 65 to 75 years; the elderly cohort included men aged older than 75 years with locally advanced disease; and the screen-detected cohort included men aged 65 years and older with screen-detected high-risk prostate cancer.

The researchers found that ADT plus RT correlated with reduced cause-specific and all-cause mortality compared with ADT alone in the RCT cohort (propensity score-adjusted hazard ratios, 0.43 and 0.63, respectively). There was no significant difference in effectiveness estimates for the RCT cohort versus those from randomized trials (P > 0.1). ADT plus RT correlated with reduced cause-specific and all-cause mortality in the elderly and screen-detected cohorts. Similar estimates were produced in instrumental variable analyses.

"Older men with locally advanced or screen-detected high-risk prostate cancer who receive ADT alone risk decrements in cause-specific and overall survival," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »